4888 Stock Overview
Engages in the research, development, manufacturing, and distribution of pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Stella Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥483.00 |
| 52 Week High | JP¥602.00 |
| 52 Week Low | JP¥229.00 |
| Beta | 1.11 |
| 11 Month Change | -5.85% |
| 3 Month Change | 9.03% |
| 1 Year Change | 55.31% |
| 33 Year Change | -21.72% |
| 5 Year Change | n/a |
| Change since IPO | -43.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4888 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -3.0% | -7.3% | -1.8% |
| 1Y | 55.3% | 9.8% | 11.4% |
Return vs Industry: 4888 exceeded the JP Pharmaceuticals industry which returned 14.7% over the past year.
Return vs Market: 4888 exceeded the JP Market which returned 11.5% over the past year.
Price Volatility
| 4888 volatility | |
|---|---|
| 4888 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 7.7% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4888's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4888's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 44 | Koki Uehara | www.stella-pharma.co.jp |
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma.
Stella Pharma Corporation Fundamentals Summary
| 4888 fundamental statistics | |
|---|---|
| Market cap | JP¥16.44b |
| Earnings (TTM) | -JP¥726.00m |
| Revenue (TTM) | JP¥285.00m |
57.7x
P/S Ratio-22.6x
P/E RatioIs 4888 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4888 income statement (TTM) | |
|---|---|
| Revenue | JP¥285.00m |
| Cost of Revenue | JP¥43.00m |
| Gross Profit | JP¥242.00m |
| Other Expenses | JP¥968.00m |
| Earnings | -JP¥726.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -21.33 |
| Gross Margin | 84.91% |
| Net Profit Margin | -254.74% |
| Debt/Equity Ratio | 27.7% |
How did 4888 perform over the long term?
See historical performance and comparison